Spotlight
Video

Risk-benefit ratio for TAS-102 in advanced treatment refractory colorectal cancer Annual Meeting GI 2016

Loading........
Description: Eric Van Cutsem, MD of University of Leuven discusses the risk-benefit ratio for TAS-102 in advanced treatment refractory colorectal cancer at ASCO GI 2016
Shared By : Gastrointestinal-Cancer-Meeting
Posted on : 01/29/16
Added : 3 years ago
Category : Colorectal Cancer